Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Portfolio Pulse from
Oncocyte Corporation reported Q4 2024 financial results, highlighting $1.5 million in pharma services revenue and $1.9 million for the full year. Key achievements include launching the GraftAssure RUO assay, securing a strategic partnership with Bio-Rad Laboratories, and advancing transplant science with expanded Medicare claims. The company is positioned to develop a regulated organ transplant rejection monitoring test kit in 2025.
March 24, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Strategic developments and financial performance suggest positive momentum for Oncocyte's market positioning in organ transplant monitoring technologies.
Positive corporate developments including strategic partnership, product launch, and funded clinical development indicate strong growth potential for Oncocyte.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100